Recent Updates
Recently added Catalysts
GOSS

Reverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells

Monday, November 11, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the positive effects of seralutinib on pulmonary artery smooth muscle cells and precision-cut lung slices in the context of pulmonary arterial hypertension (PAH). It highlights seralutinib's ability to reverse remodeling and its anti-proliferative properties, suggesting potential benefits for patients with PAH. This research may lead to improved treatment strategies for this condition.
Price reaction · baseline $0.8582 (2024-11-11 close) · hit after-hours · clean, no other GOSS news in the window
day 0 close · peak
-1.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Reverse remodeling and anti-proliferative effects of seralutinib in PAH precision-cut lung slices and pulmonary artery smooth muscle cells
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib?

Seralutinib is a drug being studied for its effects on pulmonary arterial hypertension (PAH).

How does seralutinib affect PAH?

Seralutinib has shown potential in reversing remodeling and exhibiting anti-proliferative effects in PAH.

What are precision-cut lung slices?

Precision-cut lung slices are laboratory models used to study lung tissue responses to treatments.

What is the significance of this study?

The study suggests that seralutinib may improve treatment options for patients with PAH.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib pulmonary arterial hypertension PAH anti-proliferative remodeling
Last updated: Nov 11, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →